ABC | Volume 115, Nº2, August 2020

Statement Arq Bras Cardiol. 2020; 115(2):292-301 Position Statement on the Use of Antiplatelet Agents and Anticoagulants in Patients Infected with the New Coronavirus (COVID-19) – 2020 1. GuanWJ, Ni ZY, Hu Y, LiangWH, OuCQ, He JX, et al. Clinical characteristics ofcoronavirusdisease2019 inChina.N Engl JMed.2020;382(18):1708-20. 2. Zhou F , Yu T , Du R, FanG , Liu Y , Liu Z, et al. Clinical course and risk factors for mortalityofadult inpatientswithCOVID-19 inWuhan,China:aretrospective cohort study. Lancet. 2020; 395(10229):1054-62. 3. Li B, Yang J, Zhao F , Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020; 109(5):531-8. 4. Wang D , Hu B, Hu C, Zhu F , Liu X, Zhang J , et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia inWuhan, China. JAMA. 2020; 323(11):1061-9. 5. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020 Apr 15; pii:S0735-1097(20)35008-7. 6. Costa IBSS, Bittar CS, Rizk SI, Araújo Filho AEA, Santos KAQ, Machado TIV, et al. The heart and COVID-19: what cardiologists need to know. Arq Bras Cardiol. 2020; 114(5):805-16. 7. Zhou X, Li Y, Yang O. Antiplatelet therapy after percutaneous coronary intervention in patients with COVID-19: implications from clinical features to pathologic findings. Circulation. 2020; 141(22):1736-8. 8. SeyoumM,EnawgawB,MelkuM.Humanbloodplateletsandviruses:defense mechanismandrole intheremovalofviralpathogens.Thromb J.2018 Jul17; 16:16. 9. Antoniak S. The coagulation system in host defense. The coagulation system in host defense. R es Pract Thromb Haemost. 2018; 2(3):549-57. 10. Goeijenbier M, vanWissenM, van deWeg C, Jong E, Gerdes VE, Meijers JC , et al. Review: viral infections and mechanisms of thrombosis and bleeding. J Med Virol. 2012; 84(10):1680-96. 11. Driggin E , MadhavanM V, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020; 75(18):2352-71. 12. MehraMR,DesaiSS,KuyS,HenryTD,PatelAN.Cardiovasculardisease,drug therapy, and mortality in Covid-19. N Engl J Med. 2020 May 1. [Epub ahead of print]. 13. Lippi G , Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis. Prog Cardiovasc Dis. 2020Mar 10. [Epub ahead of print]. 14. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury withmortalityinhospitalizedpatientswithCOVID-19inWuhan,China.JAMA Cardiol. 2020Mar 25:e200950. [Epub ahead of print]. 15. Akhmerov A, Marbán E. COVID-19 and the Heart. Circ Res. 2020; 126(10):1443-55. 16. RuanQ,YangK,WangW,JiangL,SongJ.Clinicalpredictorsofmortalitydueto COVID- 19 based on an analysis of data of 150 patients fromWuhan, China. Intensive CareMed. 2020Mar 03; 46:845-8. 17. GuoT , FanY , ChenM , WuX , ZhangL ,HeT ,etal.Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020Mar 27. [Epub ahead of print]. 18. PeirisJ SM, ChuC M ,ChengV CC, ChanK S ,HungI FN ,PoonL LM,etal.Clinical progressionandviral load inacommunityoutbreakofcoronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003; 361(9371):1767-72. 19. Inciardi RM, Lupi L, Zaccone G, Italia L, RaffoM , Tomasoni D, et al. Cardiac involvement in a patient with coronavírus disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27. [Epub ahead of print]. 20. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. L ancet Infect Dis. 2010; 10(2):83-92. 21. Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B, el al. ST- segment elevation in patients with Covid-19- a case series. N Engl J Med. 2020 Apr 17. [Epub ahead of print]. 22. Solomon MD, McNulty EJ , Rana JS , Leong TK, Lee C , Sung S, et al. The Covid-19 pandemic and the incidence of acute myocardial infarction. N Engl J Med. 2020 May 19. [Epub ahead of print]. 23. Baldi E, Sechi GM, Mare C , Canevari F, Brancaglione A, Primi R, et al. Out- of-hospital cardiac arrest during the Covid-19 outbreak in Italy. NEngl J Med. 2020 Apr 29. [Epub ahead of print]. 24. G , Henry BM, Sanchis-Gomar F. Physical inactivity and cardiovascular disease at the time of coronavirus disease 2019 (COVID-19). Eur J Prev Cardiol. 2020; 27(9):906-8. 25. Kochi AN , Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with Covid-19. J Cardiovasc Electrophysiol. 2020; 31(5):1003-8. 26. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(6):1421-4. 27. Dolhnikoff M, Duarte-Neto AN, Almeida Monteiro RA, Ferraz da Silva LF, Pierre deOliveira E, Saldiva PHN, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost. 2020; 18(6):1517-9. 28. Leonard-Lorant I, Delabranche X, Severac F, Helms J, Pauzet C, CollangeO , et al. Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship toD-Dimer levels. Radiology. 2020 Apr 23; 201561. [Epub ahead of print]. 29. Nascimento JHP, Gomes BFO, Resende P, Petriz JLF, Rizk SI, Costa IBSS, et al. COVID-19 and hypercoagulable state: a new therapeutic perspective. Arq Bras Cardiol. 2020; 114(5):823-7. 30. Itkonen MK, Tornio A, Lapatto-Reiniluoto O, Neuvonen M, Neuvonen PJ, Niemi M, et al. Clopidogrel increases dasabuvir exposure with or without ritonavir, and ritonavir inhibits the bioactivation of clopidogrel. C lin Pharmacol Ther. 2019; 105(1):219-28. 31. Testa S , Prandoni P, Paoletti O , Morandini R, Tala M , Dellanoce C, et al. Direct oral anticoagulant plasma levels striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the cremona experience. J Thromb Haemost. 2020; 18(6):1320-3. 32. Marsousi N, Daali Y, Fontana P , Reny J, Ancrenaz-Sirot V, Calmy A, et al. Impact of boosted antiretroviral therapy on the pharmacokinetics and efficacy of clopidogrel and prasugrel activemetabolites. Clin Pharmacokinet. 2018; 57(10):1347-54. 33. Wang Y, Zhang D, Du G, Du R, Zhao J , Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395(10236):1569-78. 34. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020; 14(1):72-3. 35. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments forcoronavirusdisease2019 (COVID-19):areview. JAMA.2020; 323(18)1824-36. 36. Geleris J, Sun Y, Platt J, Zucker J, BaldwinM , Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020 May 7. [Epub ahead of print]. 37. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020 May 11:e208630. [Epub ahead of print]. 38. TangW, Cao Z, HanM , Wang Z, Chen J, SunW , et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020 May 14. [Epub ahead of print]. 39. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020; 18(5):1094-9. References 300